Research Hypothesis: The combination of ionizing radiation and immunotherapy (durvalumab) is
well tolerated and stimulates a clinically significant pancreas-cancer specific immune
The primary objective will be to evaluate whether the combination of RT and durvalumab can
improve median PFS compared to chemotherapy historical control data in metastatic pancreas
cancer patients who have progressed through first-line chemotherapy.
The primary intent of RT in this study is to augment a pancreatic cancer-specific immune
response when given with durvalumab.